基于代谢组学探讨绝经后骨质疏松症中医证候的研究进展
Research Advances in TCM Syndromes of Postmenopausal Osteoporosis Based on Metabolomics
DOI: 10.12677/tcm.2025.145343, PDF,    科研立项经费支持
作者: 寇文超, 师建平*：内蒙古医科大学，内蒙古 呼和浩特
关键词: 绝经后骨质疏松症；中医证候；代谢组学；Postmenopausal Osteoporosis； TCM Syndromes； Metabolomics
摘要: 代谢组学作为系统生物学的重要分支，为中医证候研究提供了新的技术手段。本文首先介绍了绝经后骨质疏松症的中医证候分类、特点及相关研究，随后阐述了代谢组学在绝经后骨质疏松症的应用现状。重点分析了代谢组学在绝经后骨质疏松症中医证候研究中的具体应用，包括不同证候的代谢特征、生物标志物筛选及证候本质阐释等方面。
Abstract: As a crucial branch of systems biology, metabolomics provides a novel technical approach for studying Traditional Chinese Medicine (TCM) syndromes. This article first introduces the classification, characteristics, and related research on TCM syndromes of postmenopausal osteoporosis (PMO). Subsequently, it summarizes the current applications of metabolomics in PMO research. The focus lies in analyzing the specific roles of metabolomics in TCM syndrome studies of PMO, including the identification of metabolic characteristics across different syndromes, screening of biomarkers, and elucidation of syndrome essences. By integrating metabolomic data with TCM theory, this approach offers a holistic perspective for understanding the pathogenesis of PMO and advancing personalized TCM interventions.
文章引用：寇文超, 师建平. 基于代谢组学探讨绝经后骨质疏松症中医证候的研究进展[J]. 中医学, 2025, 14(5): 2312-2318. https://doi.org/10.12677/tcm.2025.145343

参考文献

[1] 李威, 叶佰盛, 黄振, 等. 从“天癸竭, 地道不通”谈绝经后骨质疏松症研究进展[J]. 中国中西医结合杂志, 2024, 44(5): 623-626.
[2] 谢雁鸣, 刘峘, 姜俊杰, 等. 绝经后骨质疏松症中医临床实践指南(征求意见稿) [J]. 中国中药杂志, 2021, 46(22): 5992-5998.
[3] 黎征鹏, 章晓云, 曾浩, 等. 基于“脏腑-骨痿”理论探讨绝经后骨质疏松症的发病机制[J]. 世界中医药, 2024, 19(19): 3015-3022.
[4] 中华中医药学会. 绝经后骨质疏松症(骨痿)中医药诊疗指南(2019年版) [J]. 中医正骨, 2020, 32(2): 1-13.
[5] 中华医学会骨质疏松和骨矿盐疾病分会, 章振林. 原发性骨质疏松症诊疗指南(2022) [J]. 中国全科医学, 2023, 26(14): 1671-1691.
[6] 许云腾, 张欣, 段辛威, 等. 基于“神经-内分泌-免疫”功能网络探讨从肾论治绝经后骨质疏松症的科学内涵[J]. 中华中医药杂志, 2023, 38(3): 974-978.
[7] 唐德志, 赵东峰, 原淳淳, 等. 中医“肾主骨”理论指导下“肾骨系统”的构建和价值[J]. 中国骨质疏松杂志, 2022, 28(6): 873-880.
[8] 钟建春, 谢兴文, 李鼎鹏, 等. 中药植物雌激素防治绝经后骨质疏松研究概况[J]. 时珍国医国药, 2021, 32(7): 1723-1726.
[9] 黄晋, 李建国, 谢兴文, 等. 中药复方治疗绝经后骨质疏松症的临床研究概况[J]. 中国骨质疏松杂志, 2019, 25(2): 277-280.
[10] 于雪冰, 马建强, 汪栋, 等. 六味地黄丸治疗绝经后骨质疏松症肾阴虚证对骨钙素、骨密度及JAK/STAT信号通路的影响[J]. 中药材, 2020, 43(3): 734-737.
[11] 胡阳, 宋敏, 李凯, 等. 左归丸及其组方治疗绝经后骨质疏松症的基础研究进展[J]. 中华中医药学刊, 2023, 41(12): 86-89.
[12] 刘朋, 杨鸫祥, 于冬冬, 等. 基于“阴常不足”理论探讨滋阴药物治疗绝经后骨质疏松症研究进展[J]. 辽宁中医药大学学报, 2021, 23(6): 95-98.
[13] 梁壮, 董博, 袁普卫, 等. 右归丸对绝经后骨量减少肾阳虚型的临床研究[J]. 中国骨质疏松杂志, 2022, 28(8): 1164-1168, 1174.
[14] 张倩, 杨旭, 王媛, 等. 金匮肾气丸对去势大鼠骨微结构及ALP、OPG、IL-6的影响[J]. 中国骨质疏松杂志, 2020, 26(10): 1475-1480.
[15] 郑礼, 秦大平, 张朋威, 等. 绝经后骨质疏松症肾虚血瘀型的认识和中医药防治策略研究[J]. 中国骨质疏松杂志, 2022, 28(12): 1865-1868.
[16] 卞庆来, 邹小娟, 沈霖. 青娥丸治疗绝经后骨质疏松症肾虚血瘀证的疗效观察[J]. 中华中医药杂志, 2018, 33(1): 308-312.
[17] 王晓燕, 常时新, 李冠武, 等. 经方青娥丸对去势大鼠骨质 疏松作用机制的实验研究[J]. 中国骨质疏松杂志, 2017, 23(2): 197-202.
[18] 王晓燕, 常时新, 李冠武, 等. 青娥丸对去卵巢大鼠骨质疏 松骨微循环的作用机制研究[J]. 环球中医药, 2017, 10(7): 802-807.
[19] 井媛媛, 支英杰, 谢雁鸣, 等. 中药复方治疗绝经后骨质疏松症疗效及其机制的研究进展[J]. 中国骨质疏松杂志, 2023, 29(2): 268-272, 276.
[20] Zhao, Z., Cai, Z., Chen, A., Cai, M. and Yang, K. (2022) Application of Metabolomics in Osteoporosis Research. Frontiers in Endocrinology, 13, Article 993253. [Google Scholar] [CrossRef] [PubMed]
[21] Qi, H., Bao, J., An, G., Ouyang, G., Zhang, P., Wang, C., et al. (2016) Association between the Metabolome and Bone Mineral Density in Pre-and Post-Menopausal Chinese Women Using GC-MS. Molecular BioSystems, 12, 2265-2275. [Google Scholar] [CrossRef] [PubMed]
[22] Miyamoto, T., Hirayama, A., Sato, Y., Koboyashi, T., Katsuyama, E., Kanagawa, H., et al. (2017) A Serum Metabolomics-Based Profile in Low Bone Mineral Density Postmenopausal Women. Bone, 95, 1-4. [Google Scholar] [CrossRef] [PubMed]
[23] Watanabe, K., Iida, M., Harada, S., Kato, S., Kuwabara, K., Kurihara, A., et al. (2022) Metabolic Profiling of Charged Metabolites in Association with Menopausal Status in Japanese Community-Dwelling Midlife Women: Tsuruoka Metabolomic Cohort Study. Maturitas, 155, 54-62. [Google Scholar] [CrossRef] [PubMed]
[24] Tan, B., Cheng, Y., Li, J., Zheng, Y., Xiao, C., Guo, H., et al. (2025) Combining Untargeted and Targeted Metabolomic Profiling Reveals Principal Differences between Osteopenia, Osteoporosis and Healthy Controls. Aging Clinical and Experimental Research, 37, Article No. 28. [Google Scholar] [CrossRef] [PubMed]
[25] Moffett, J.R., Puthillathu, N., Vengilote, R., Jaworski, D.M. and Namboodiri, A.M. (2020) Acetate Revisited: A Key Biomolecule at the Nexus of Metabolism, Epigenetics and Oncogenesis—Part 1: Acetyl-Coa, Acetogenesis and Acyl-Coa Short-Chain Synthetases. Frontiers in Physiology, 11, Article 580167. [Google Scholar] [CrossRef] [PubMed]
[26] PARK, M., CHOI, H.K. and AN, J.H. (2020) Taurine Activates BMP-2/Wnt3a-Mediated Osteoblast Differentiation and Mineralization via Akt and MAPK Signaling. Iranian Journal of Public Health, 48, 1960-1970. [Google Scholar] [CrossRef] 
[27] Qi, T., Li, L. and Weidong, T. (2021) The Role of Sphingolipid Metabolism in Bone Remodeling. Frontiers in Cell and Developmental Biology, 9, Article 752540. [Google Scholar] [CrossRef] [PubMed]
[28] Gao, K., Mu, C., Farzi, A. and Zhu, W. (2020) Tryptophan Metabolism: A Link between the Gut Microbiota and Brain. Advances in Nutrition, 11, 709-723. [Google Scholar] [CrossRef] [PubMed]
[29] D’Amelio, P. and Sassi, F. (2017) Gut Microbiota, Immune System, and Bone. Calcified Tissue International, 102, 415-425. [Google Scholar] [CrossRef] [PubMed]
[30] Wen, K., Tao, L., Tao, Z., Meng, Y., Zhou, S., Chen, J., et al. (2020) Fecal and Serum Metabolomic Signatures and Microbial Community Profiling of Postmenopausal Osteoporosis Mice Model. Frontiers in Cellular and Infection Microbiology, 10, Article 535310. [Google Scholar] [CrossRef] [PubMed]
[31] Kennedy, P.J., Cryan, J.F., Dinan, T.G. and Clarke, G. (2017) Kynurenine Pathway Metabolism and the Microbiota-Gut-Brain Axis. Neuropharmacology, 112, 399-412. [Google Scholar] [CrossRef] [PubMed]
[32] 谢林碧, 赵欢, 李东晓. 组学技术在中药抗骨质疏松机理研究中的应用[J]. 中药药理与临床, 2023, 39(3): 101-106.
[33] 郭胜男, 戚晓楠, 姚啸生, 等. UPLC-MS/MS对肾阳虚原发性骨质疏松临床代谢标志物筛查研究[J]. 中国骨质疏松杂志, 2022, 28(10): 1410-1415.
[34] 刘晏东, 邓强, 彭冉东, 等. 代谢组学对肌骨衰减疾病的研究进展[J]. 中国骨质疏松杂志, 2023, 29(10): 1513-1518, 1560.
[35] 尹恒, 王建伟, 张亚峰, 等. UPLC-MS对骨质疏松症阴虚证临床代谢标志物筛查研究[J]. 中国骨质疏松杂志, 2021, 27(9): 1316-1322.
[36] 徐琬梨, 李肖飞, 田琪. 基于代谢组学的绝经后骨质疏松症实性证素研究[J]. 辽宁中医杂志, 2020, 47(3): 97-101.
[37] 盛玲玲, 李先娜, 霍金海, 等. 基于尿液代谢组学研究豆豉抗骨质疏松作用机制[J]. 中国药理学通报, 2020, 36(2): 182-190.
[38] 孙娜, 刘瑶, 徐琬梨, 等. 基于“骨肉不相亲”理论探讨绝经后骨质疏松症的代谢组学研究[J]. 中医药信息, 2022, 39(9): 1-7.
[39] 李肖飞, 徐琬梨. 基于证素辨证的绝经后骨质疏松症代谢组学研究[J]. 吉林中医药, 2020, 40(5): 620-624.
[40] 梁华, 王燕, 朱明雪, 等. 金匮肾气丸及六味地黄丸对自然衰老小鼠血浆代谢物的影响[J]. 中国中医药信息杂志, 2020, 27(6): 50-55.
[41] Zhang, A., Ma, Z., Sun, H., Zhang, Y., Liu, J., Wu, F., et al. (2019) High-Throughput Metabolomics Evaluate the Efficacy of Total Lignans from Acanthophanax senticosus Stem against Ovariectomized Osteoporosis Rat. Frontiers in Pharmacology, 10, Article 553. [Google Scholar] [CrossRef] [PubMed]
[42] 刘文静, 杨娟, 黄美雅, 等. 健骨颗粒抗去卵巢大鼠骨质疏松的血清代谢组学研究[J]. 中国骨质疏松杂志, 2021, 27(12): 1820-1826.
[43] 刘文静, 杨娟, 张楚天, 等. 巴戟天抗去卵巢骨质疏松大鼠的血清代谢组分析[J]. 中国药理学通报, 2022, 38(3): 446-453.
[44] 张海永, 黄景文, 谢冰颖, 等. 骨疏康治疗去卵巢大鼠骨质疏松的腰椎代谢组学分析[J]. 中国组织工程研究, 2022, 26(32): 5185-5190.
[45] 谢丽华, 柴昊, 李生强, 等. 联合蛋白质组学和代谢组学探讨绝经后骨质疏松症肾虚证的分子机制[J]. 中华中医药杂志, 2023, 38(11): 5519-5523.